Literature DB >> 376360

Paradoxical effects of D-Trp6-luteinizing hormone-releasing hormone on the hypothalamic-pituitary-gonadal axis in immature female rats.

J A Vilchez-Martinez, E Pedroza, A Arimura, A V Schally.   

Abstract

The effect of administration of a superactive and long-acting analog of luteinizing hormone-releasing hormone (LH-RH), D-Trp6-LH-RH, in doses of 0.05 or 1 microgram/day for 10 days on the hypothalamic-pituitary-gonadal axis was studied in immature female rats. Treatment with a 0.05-microgram dose of analog produced few changes as compared with the control group. Treatment with 1 microgram of D-Trp6-LH-RH did not affect the body weight or the pituitary weight, but increased ovarian weight and decreased uterine weight; elevated serum gonadotropin levels; and lowered the pituitary LH content. This depletion of pituitary LH content was associated with a low pituitary responsiveness to LH-RH. Serum estradiol levels were not modified, suggesting that decreased uterine weight reflects a direct and extrapituitary effect of this analog. The hypothalamic LH-RH content was higher, indicating a possible inhibition of the release of endogenous LH-RH. A delay in vaginal opening was also observed. This indicates that large doses of D-Trp6-LH-RH may interfere with the process of puberty in rats. These findings extend other reports about the paradoxical antifertility effects of large doses of stimulatory analogs of LH-RH.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 376360     DOI: 10.1016/s0015-0282(16)44061-6

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

Review 1.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

2.  Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.

Authors:  A V Schally; T W Redding; A M Comaru-Schally
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

3.  Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.

Authors:  M G de Quijada; T W Redding; D H Coy; I Torres-Aleman; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

4.  Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.

Authors:  T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

5.  Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  E Korkut; L Bokser; A M Comaru-Schally; K Groot; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

Review 6.  Evolution of androgen receptor targeted therapy for advanced prostate cancer.

Authors:  Yien Ning Sophia Wong; Roberta Ferraldeschi; Gerhardt Attard; Johann de Bono
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

Review 7.  Cardiovascular effects of hormone therapy for prostate cancer.

Authors:  Jason F Lester; Malcolm D Mason
Journal:  Drug Healthc Patient Saf       Date:  2015-07-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.